Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

Phase 3

Completed

• Conditions: Crohn's Disease

• Registration Number: NCT00032786
• Lead Sponsor: Biogen

Brief Summary

The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderate to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-03
• Study First Submitted: 2002-04-03
• Study First Submitted QC: 2002-04-03
• Study First Posted: 2002-04-04
• Primary Completion: 2004-03
• Study Completion: 2004-03
• Status Verified: 2012-03
• Last Update Submitted: 2016-06-14
• Last Update Posted: 2016-06-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL